This move is archived. Current quotes and coverage live on the stock page.
Get MDP alerts:
Medexus Pharmaceuticals Inc is making waves on the TSX with a significant price jump.
Medexus Pharmaceuticals Inc (MDP.TO) is experiencing a remarkable surge in its stock price, rising by 8.47% in today's trading session. As investors take notice, the company's market cap now stands at approximately CA$160 million, reflecting growing confidence in its future prospects.
Investor takeaway: The recent price increase suggests renewed investor interest in Medexus, potentially driven by positive sentiment surrounding its product performance.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$157.13M
52W high
$5.50
52W low
$2.51
1W change
-1.57%
Beta
1.83
Analyst Price Targets
Based on analyst covering MDP · as of Sep 17, 2026
Wall Street analysts forecast MDP stock price to rise 45.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+45.0% Upside
Current Price
C$5.00
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
30.8%
Annualized
90-Day Vol
38.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.34 | C$4.80 – C$5.94 |
| 60 trading days | C$5.67 | C$4.87 – C$6.59 |
| 90 trading days | C$6.01 | C$5.00 – C$7.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Medexus Pharmaceuticals Inc stock rises 8.47% today
Advertisement
This increase marks a significant uptick in investor interest, potentially signaling a turnaround for the company.
Bull case
The strong performance of GRAFAPEX (treosulfan) for Injection has been a key driver for Medexus. This indicates robust demand and the potential for continued revenue growth, which is encouraging for investors.
Bear case
Despite today's gains, Medexus still faces challenges. The company has a negative profit margin and needs consistent product performance to maintain investor confidence.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
